Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …

In the United States,[68Ga] Ga-DOTA-TOC has been approved by the Food and Drug
Administration (FDA) in 2019 as the first 68Ga-radiopharmaceutical for imaging of …

Importance Targeted alpha therapy attempts to deliver systemic radiation selectively to
cancer cells while minimizing systemic toxic effects and may lead to additional treatment …

Targeted alpha therapy is an oncological treatment, where cytotoxic doses of alpha radiation
are locally delivered to tumor cells, while the surrounding healthy tissue is minimally …

Complex molecular and metabolic phenotypes depict cancers as a constellation of different
diseases with common themes. Precision imaging of such phenotypes requires flexible and …

α-Emitting radionuclides have been approved for cancer treatment since 2013, with
increasing degrees of success. Despite this clinical utility, little is known regarding the …

Introduction: The combination of a targeted biomolecule that specifically defines the target
and a radionuclide that delivers a cytotoxic payload offers a specific way to destroy cancer …

Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a
very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding …

Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-
particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or …

In recent years, advancement in genetics has profoundly helped to gain a more
comprehensive molecular, pathogenic, and prognostic picture of pheochromocytomas and …